Company profile

Ticker
GILD
Exchange
Website
CEO
Daniel P. O'Day
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
943047598

GILD stock data

(
)

Calendar

6 Aug 20
27 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
17 Aug 20 Parsey Merdad Common Stock Sell Dispose S Yes 68.32 182 12.43K 0
15 Aug 20 Parsey Merdad Common Stock Grant Aquire A No 57.426 182 10.45K 182
10 Aug 20 Wilfong Diane E. Common Stock Payment of exercise Dispose F No 68.51 1,384 94.82K 13,382
10 Aug 20 Wilfong Diane E. Common Stock Option exercise Aquire M No 0 3,345 0 14,766
10 Aug 20 Wilfong Diane E. RSU Common Stock Option exercise Dispose M No 0 3,345 0 19,401
10 Aug 20 Dickinson Andrew D Common Stock Payment of exercise Dispose F No 68.51 1,022 70.02K 14,639
10 Aug 20 Dickinson Andrew D Common Stock Option exercise Aquire M No 0 2,306 0 15,661
10 Aug 20 Dickinson Andrew D RSU Common Stock Option exercise Dispose M No 0 2,306 0 35,164
24 Jul 20 Mercier Johanna Common Stock Payment of exercise Dispose F No 73.64 3,587 264.15K 3,918
24 Jul 20 Mercier Johanna Common Stock Option exercise Aquire M No 0 7,505 0 7,505
78.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1574 1612 -2.4%
Opened positions 152 253 -39.9%
Closed positions 190 167 +13.8%
Increased positions 606 611 -0.8%
Reduced positions 662 620 +6.8%
13F shares
Current Prev Q Change
Total value 877.01B 843.64B +4.0%
Total shares 977.79M 988.79M -1.1%
Total puts 23.62M 22.95M +2.9%
Total calls 20.07M 27.66M -27.4%
Total put/call ratio 1.2 0.8 +41.8%
Largest owners
Shares Value Change
Capital Research Global Investors 125.36M $9.64B +30.6%
BLK BlackRock 115.83M $8.91B +14.4%
Vanguard 104.81M $8.06B -2.1%
STT State Street 58.03M $4.46B +2.2%
Capital International Investors 57.14M $4.4B +1.4%
Capital World Investors 43.5M $3.35B -6.1%
Geode Capital Management 19.67M $1.51B -1.1%
BK Bank of New York Mellon 16.85M $1.3B -10.9%
NTRS Northern Trust 16.08M $1.24B +3.4%
FMR 12.6M $969.64M +14.4%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 125.36M +29.37M +30.6%
BLK BlackRock 115.83M +14.62M +14.4%
BEN Franklin Resources 7.14M -6.51M -47.7%
California Public Employees Retirement System 10.53M +6.18M +141.9%
Nuveen Asset Management 6.37M -6.07M -48.8%
FHI Federated Hermes 2.21M -4.93M -69.1%
JPM JPMorgan Chase & Co. 2.77M -4.32M -60.9%
Renaissance Technologies 8.9M -3.63M -29.0%
Capital World Investors 43.5M -2.83M -6.1%
Dodge & Cox 12.59M -2.52M -16.7%

Financial report summary

?
Risks
  • A substantial portion of our revenues is derived from sales of our HIV products. If we are unable to increase or maintain our HIV sales, then our results of operations may be adversely affected.
  • If we fail to develop and commercialize new products or expand the indications for existing products, our prospects for future revenues and our results of operations may be adversely affected.
  • Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the recent coronavirus disease 2019 (“COVID-19”) outbreak.
  • We face risks related to the development, manufacturing and distribution of remdesivir as a treatment for COVID-19, which has not been approved by FDA and has not been demonstrated to be safe or effective for any use.
  • Our inability to accurately predict demand for our products and fluctuations in purchasing patterns or wholesaler inventories makes it difficult for us to accurately forecast sales and may cause our forecasted revenues and earnings to fluctuate, which could adversely affect our financial results and stock price.
  • We face significant competition.
  • We may be required to pay significant damages and royalty payments as a result of ongoing litigation related to Yescarta and Biktarvy.
  • Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.
  • Our existing products are subject to reimbursement from government agencies and other third parties, and we may be required to provide rebates and other discounts on our products, which may result in an adjustment to our product revenues. Pharmaceutical pricing and reimbursement pressures may adversely affect our profitability and our results of operations.
  • Laws and regulations applicable to the health care industry could impose new obligations on us, require us to change our business practices and restrict our operations in the future.
  • Yescarta, a chimeric antigen receptor (“CAR”) T cell therapy, represents a novel approach to cancer treatment that creates significant challenges for us, which may impact our ability to increase sales of Yescarta.
  • We have engaged in, and may in the future engage in, business acquisitions, licensing arrangements, collaborations, options, equity investments, disposals of our assets and other strategic transactions, which could cause us to incur significant expenses and could adversely affect our financial condition and results of operations.
  • We face risks associated with our global operations, which may adversely affect our financial condition and results of operations.
  • If significant safety issues arise for our marketed products or our product candidates, our reputation may be harmed and our future sales may be reduced, which could adversely affect our results of operations.
  • Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.
  • We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption, which may adversely affect our prospects for future revenue growth and our results of operations.
  • We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.
  • Our success depends to a significant degree on our ability to defend our patents and other intellectual property rights both domestically and internationally. We may not be able to obtain effective patents to protect our technologies from use by competitors.
  • Our success depends in large part on our ability to operate without infringing upon the patents or other proprietary rights of third parties.
  • Manufacturing problems, including at our third-party manufacturers and corporate partners, could cause inventory shortages and delay product shipments and regulatory approvals, which may adversely affect our results of operations.
  • We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.
  • Imports from countries where our products are available at lower prices and unapproved generic or counterfeit versions of our products could have a negative impact on our reputation and business.
  • Expensive litigation and government investigations have increased our expenses which may continue to reduce our earnings.
  • We may face significant liability resulting from our products and such liability could materially reduce our earnings.
  • If we fail to attract, develop and retain highly qualified personnel, our business and operations may be adversely affected.
  • We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.
  • Changes in our effective income tax rate could reduce our earnings.
  • There can be no assurance that we will continue to pay dividends or repurchase stock.
Management Discussion
  • Total product sales decreased by 10% to $5.1 billion for the three months ended June 30, 2020, compared to $5.6 billion for the same period in 2019, primarily due to lower sales volume of HCV products due to the COVID-19 pandemic, which led to fewer HCP visits and screenings, and lower sales of Letairis and Ranexa after generic entries in the first half of 2019. The decreases were also due to approximately $160 million of favorable adjustments for statutory rebates primarily related to HCV and HIV sales recorded in Europe in the second quarter of 2019, which did not reoccur in 2020. The decreases were partially offset by underlying demand growth in the core HIV business, with continued patient uptake of Biktarvy and the increased usage of Descovy for PrEP.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: accrual, airline, America, antagonist, azacitidine, baricitinib, bear, behavior, biased, biology, Breakthrough, building, checkpoint, CHMP, clearance, Committee, compassionate, constrained, contemplating, core, DaVita, deep, differentiation, DOJ, dynamic, earliest, England, EP, equitable, Eurodollar, faster, finalization, formulation, franchise, gradual, harbor, HCP, healthy, highlighting, home, immunotherapy, incidence, indolent, inflation, inhaled, instruct, Instrument, intolerant, investor, JAK, Javier, Journal, jyseleca, killer, Labour, lesser, mandatory, momentum, morale, North, notified, nursing, occupancy, outpatient, partnership, pathway, penalty, perspective, pharmacy, physical, Pionyr, pneumonia, pregnant, prepay, published, pull, reclassification, refiled, reoccur, reserved, restarted, Rodriguez, route, rulemaking, satisfaction, secondary, solution, Superior, tecartustm, Teneobio, TIGIT, Tizona, tumor, Tuning, UniAb, unsealed, unvested, upfront, variation, veklury, vial, wave
Removed: ASC, begun, biosimilar, Blueprint, body, bowel, chronic, consisted, create, deductible, discontinuance, enrolled, EU, expansion, Eyetech, implementing, improve, index, initiative, LEXISCAN, LIBOR, MACUGEN, MINE, monitor, participating, physician, profit, QUALITATIVE, QUANTITATIVE, reached, registered, reviewed, Secretary, sharing, slightly, TAMIFLU, UNREGISTERED